Surgery (Austin & Northern Health) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 1013
  • Item
    Thumbnail Image
    AIDS RELATED KAPOSIS-SARCOMA PRESENTING AS ULCERATIVE-COLITIS AND COMPLICATED BY TOXIC MEGACOLON
    BIGGS, BA ; CROWE, SM ; LUCAS, CR ; RALSTON, M ; THOMPSON, IL ; HARDY, KJ (BRITISH MED JOURNAL PUBL GROUP, 1987-10-01)
    Gastrointestinal Kaposi's sarcoma is a well described and usually asymptomatic manifestation of the acquired immune deficiency syndrome. We report a patient who had extensive colonic Kaposi's sarcoma and presented with an ulcerative colitis like illness. Total colectomy was subsequently required as an emergency procedure for toxic megacolon. The patient remains well on maintenance interferon therapy 21 months after surgery.
  • Item
    Thumbnail Image
    Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
    Walpole, I ; Lee, B ; Shapiro, J ; Thomson, B ; Lipton, L ; Ananda, S ; Usatoff, V ; Mclachlan, S-A ; Knowles, B ; Fox, A ; Wong, R ; Cooray, P ; Burge, M ; Clarke, K ; Pattison, S ; Nikfarjam, M ; Tebbutt, N ; Harris, M ; Nagrial, A ; Zielinski, R ; Chee, CE ; Gibbs, P (WILEY, 2023-02-01)
    Background: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable. Method: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan–Meier analysis. Results: The PURPLE database included 754 cases with localised PDAC, including 148 (20%) cases with borderline resectable pancreatic cancer (BRPC). Of the 148 BRPC patients, 44 (30%) underwent immediate surgery, 80 (54%) received NA chemotherapy, and 24 (16%) were inoperable. The median age of NA therapy patients was 63 years and FOLFIRINOX (53%) was more often used as NA therapy than gemcitabine/nab-paclitaxel (31%). Patients who received FOLFIRINOX were younger than those who received gemcitabine/nab-paclitaxel (60 years vs. 67 years, p =.01). Surgery was performed in 54% (43 of 80) of BRPC patients receiving NA chemotherapy, with 53% (16 of 30) achieving R0 resections. BRPC patients undergoing surgery had a median OS of 30 months, and 38% (9 of 24) achieved R0 resection. NA chemotherapy patients had a median OS of 20 months, improving to 24 months versus 10 months for patients receiving FOLFIRINOX compared to gemcitabine/nab-paclitaxel (Hazard Ratio (HR).3, p <.0001). Conclusions: NA chemotherapy use in BRPC is increasing in Australia. One half of patients receiving NA chemotherapy proceed to curative resection, with 53% achieving R0 resections. Patients receiving Infusional 5-flurouracil, Irinotecan and Oxaliplatin (FOLIRINOX) had increased survival than gemcitabine/nab-paclitaxel. Treatment strategies are being explored in the MASTERPLAN and DYNAMIC-Pancreas trials.
  • Item
    Thumbnail Image
    Temporal changes in the epidemiology of sepsis-related intensive care admissions from the emergency department in Australia and New Zealand
    Jones, D ; Moran, J ; Udy, A ; Pilcher, D ; Delaney, A ; Peake, SL (WILEY, 2022-07-03)
    OBJECTIVES: The Australasian Resuscitation in Sepsis Evaluation (ARISE) study researched septic shock treatment within EDs. This study aims to evaluate whether: (i) conduct of the ARISE study was associated with changes in epidemiology and care for adults (≥18 years) admitted from EDs to ICUs with sepsis in Australia and New Zealand; and (ii) such changes differed among 45 ARISE trial hospitals compared with 120 non-trial hospitals. METHODS: Retrospective study using interrupted time series analysis in three time periods; 'Pre-ARISE' (January 1997 to December 2007), 'During ARISE' (January 2008 to May 2014) and 'Post-ARISE' (June 2014 to December 2017) using data from the Australian and New Zealand Intensive Care Society Adult Patient Database. RESULTS: Over 21 years there were 54 121 ICU admissions from the ED with sepsis; which increased from 8.1% to 16.4%; 54.6% male, median (interquartile range) age 66 (53-76) years. In the pre-ARISE period, pre-ICU ED length of stay (LOS) decreased in trial hospitals but increased in non-trial hospitals (P = 0.174). During the ARISE study, pre-ICU ED LOS declined more in trial hospitals (P = 0.039) as did the frequency of mechanical ventilation in the first 24 h (P = 0.003). However, ICU and hospital LOS, in-hospital mortality and risk of death declined similarly in both trial and non-trial hospitals. CONCLUSIONS: Sepsis-related admissions increased from 8.1% to 16.4%. During the ARISE study, there was more rapid ICU admission and decreased early ventilation. However, these changes were not sustained nor associated with decreased risk of death or duration of hospitalisation.
  • Item
    Thumbnail Image
    Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer
    Harvey, M ; Ong, WL ; Chao, M ; Udovicich, C ; McBride, S ; Bolton, D ; Eastham, J ; Perera, M (WILEY, 2023-03)
    OBJECTIVES: To provide a comprehensive narrative review of the published data on the impact of hydrogel spacers on rectal dosimetry and toxicity and to outline the practicalities of inserting hydrogel spacers. RESULTS: A growing body of evidence suggests that the administration of hydrogel spacers is safe and is associated with limited peri-operative morbidity. The impact on rectal dosimetry has been clearly established and use of hydrogel spacers is associated with reduced rectal morbidity. These results have been corroborated by several Phase II and III clinical trials and subsequent meta-analysis. There are several areas for future research, including the role of hydrogel spacers in prostate stereotactic beam radiotherapy and post-radiotherapy local recurrence. CONCLUSIONS: Hydrogel spacers provide a low-morbidity method to potential reduce rectal toxicity after radiation therapy in men with prostate cancer. Data outlining sexual function and oncological outcomes are limited to date. Future studies, currently being conducted, may provide further clarification of the role of hydrogel spacers in prostate cancer management.
  • Item
    Thumbnail Image
    Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer Comment
    O'Brien, JS ; McVey, A ; Kelly, BD ; Jenjitranant, P ; Buteau, J ; Hofman, MS ; Kasivisvanithan, V ; Eapen, R ; Moon, D ; Murphy, DG ; Lawrentschuk, N (WILEY, 2022-07-12)
  • Item
    Thumbnail Image
    A glass half-full: positive impacts of the COVID-19 pandemic on the delivery of public hospital urology care Comment
    Chinni, V ; El-Khoury, HJ ; Lawrentschuk, N ; Bolton, D (WILEY, 2022-03-29)
  • Item
    Thumbnail Image
    Junior doctors voice strong desire for clinical ethics teaching
    Schnall, JA ; Drewett, G ; Heynemann, S ; McDougall, R ; Ko, D (WILEY, 2022-01-01)
  • Item
    Thumbnail Image
    Registrar triage, communication and moral distress during end-of-life care rapid response team calls in a teaching hospital
    Callahan, S ; Moran, J ; See, E ; Jones, D ; Eastwood, GM ; Warrillow, S (WILEY, 2022-12)
    BACKGROUND: Approximately one-third of rapid response teams (RRT) involve end-of-life care (EOLC) issues. Intensive care unit (ICU) registrar experience in such calls is underinvestigated. AIMS: To evaluate the proportion of RRT calls triaged as relating to EOLC issues, issues around communication regarding prognostication, registrar self-reported moral distress and associations between RRT EOLC classification and patient outcomes. METHODS: Prospective observational study of RRT calls in a tertiary referrals hospital between December 2016 and January 2017 using a standardised case report form and data from an electronic RRT database. RESULTS: There were 401 RRT calls in the study period, and data were available for 270 (67%) calls, of which 72%, 10% and 18% were triaged as 'obviously not EOLC call', 'obvious EOLC call' and 'uncertain EOLC call' respectively. Most discussions regarding prognostication occurred between registrars, and more than half (55%) were with a covering doctor. Consensus on prognostication was achieved in 93% cases. Registrars reported distress in 19% of calls that obviously related to EOLC and 22% of calls that were uncertain, compared with <1% of calls that were obviously not relating to EOLC. Inhospital mortality was 6%, 67% and 39% for obviously not EOLC, obvious EOLC and uncertain EOLC calls respectively. CONCLUSIONS: EOLC issues occur commonly in RRT calls and are often associated with moral distress to ICU registrars. Although consensus on prognostication is usually achieved, conversations often involve covering doctors. These issues impact on the ICU registrar experience of RRT calls and require further exploration.
  • Item
    Thumbnail Image
    Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus
    Maharaj, AD ; Lubel, J ; Lam, E ; Clark, PJ ; Duncan, O ; George, J ; Jeffrey, GP ; Lipton, L ; Liu, H ; McCaughan, G ; Neo, E-L ; Philip, J ; Strasser, S ; Stuart, K ; Thompson, A ; Tibballs, J ; Tu, T ; Wallace, MC ; Wigg, A ; Wood, M ; Zekry, A ; Greenhill, E ; Ioannou, LJ ; Ahlenstiel, G ; Bowers, K ; Clarke, SJ ; Dev, A ; Fink, M ; Goodwin, M ; Karapetis, CS ; Levy, MT ; Muller, K ; O'Beirne, J ; Pryor, D ; Seow, J ; Shackel, N ; Tallis, C ; Butler, N ; Olynyk, JK ; Reed-Cox, K ; Zalcberg, JR ; Roberts, SK (JOHN WILEY & SONS LTD, 2022-09-25)
    Although there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study was to develop a core set of quality indicators (QIs) to underpin the management of HCC. We undertook a modified, two-round, Delphi consensus study comprising a working group and experts involved in the management of HCC as well as consumer representatives. QIs were derived from an extensive review of the literature. The role of the participants was to identify the most important and measurable QIs for inclusion in an HCC clinical quality registry. From an initial 94 QIs, 40 were proposed to the participants. Of these, 23 QIs ultimately met the inclusion criteria and were included in the final set. This included (a) nine related to the initial diagnosis and staging, including timing to diagnosis, required baseline clinical and laboratory assessments, prior surveillance for HCC, diagnostic imaging and pathology, tumor staging, and multidisciplinary care; (b) thirteen related to treatment and management, including role of antiviral therapy, timing to treatment, localized ablation and locoregional therapy, surgery, transplantation, systemic therapy, method of response assessment, and supportive care; and (c) one outcome assessment related to surgical mortality. Conclusion: We identified a core set of nationally agreed measurable QIs for the diagnosis, staging, and management of HCC. The adherence to these best practice QIs may lead to system-level improvement in quality of care and, ultimately, improvement in patient outcomes, including survival.
  • Item
    Thumbnail Image
    Liver Machine Perfusion-When Physiopathology Matters
    Furtado, R ; Weinberg, L ; Perini, MV (MDPI, 2022-09-01)
    Liver transplantation (LT) has become a victim of its own success [...].